| |
Safety and Efficacy of Dolutegravir and Maraviroc Plus Background Therapy in HIV-1 Treatment-Experienced Participants
|
| |
| |
Reported by Jules Levin
22nd Annual Conference of the British HIV Association; April 19-22, 2016; Manchester Central, UK
M Prakash,1 J Huang,2 J Lim,3 J Koteff,4 C Trezza,4 S Griffith,4 M Ait-Khaled,1 B Wynne,5 M Gartland,4 A Clark,1 M Aboud1
1ViiV Healthcare, London, UK; 2GlaxoSmithKline, Mississauga, ON, Canada; 3GlaxoSmithKline, Stockley Park, UK; 4ViiV Healthcare, Research Triangle Park, NC, USA; 5ViiV Healthcare, Collegeville, PA, USA
|
|
| |
| |
|
|
|
